Geometry Dash APK Hill Climb Racing APK
41.2 F
New York
Friday, December 9, 2022

CytoDyn Inc (OTCMKTS:CYDY) Hits 4-Month High As Covid-19 Fear Grows

Must read

Asia Broadband Inc (OTCMKTS:AABB) Is Up 1100% This year: What’s The Buzz?

There are some stocks that have managed to clock massive over the course of the past month or so and one of...

Blockchain Technologies Ltd (OTCMKTS:HVBTF) Makes A Stunning Move on Blockchain Optimism

The cryptocurrency boom has sustained for many months now and it anything; it is expected to continue in the future.

Bombardier, Inc. (OTCMKTS:BDRBF) Continues to Gain Momentum and Strength

Many stocks have managed to record significant gains in recent months and one that often flies under the radar is Bombardier,...

Grayscale Bitcoin Trust (Btc) (GBTC) Makes Big Move As Bitcoin Goes Wild

Bitcoin, the world’s biggest cryptocurrency by market cap, has been in the middle of a remarkable rally for the past few months...

The coronavirus pandemic unleashed chaos all over the world and also in the markets, however, some biotech companies working on treatments for coronavirus patients saw their stocks soar.

One such company is CytoDyn Inc (OTCMKTS:CYDY), which has been working on its product leronlimab that is meant for the treatment of such patients.

Recent Developments

On Monday, CytoDyn Inc (OTCMKTS:CYDY) went on an impressive rally and soared by as much as 20% on the back of a significant announcement from the company last week. It hit its highest level in four months and took its gains over the course of the past three weeks to 155%.

Back on December 17, the company announced that it completed its enrolment for the Phase 3 registrational study with regards to the possibility of using leronlimab as a treatment for patients with severe to critical COVID 19 symptoms. It goes without saying that it is a significant milestone for CytoDyn and the excitement among investors is understandable.

In total, the company has enrolled as many as 390 patients for this study and the data is going to be analyzed by experts over a period of 28 days. It has also been revealed that the results of the study are going to be released by CytoDyn at some point in the middle of January in 2021.

CytoDyn Inc (OTCMKTS:CYDY) has been one of the better performers this year so far and has recorded gains of as much as 246%. It is a highly impressive performance considering the fact that the wider industry grew by only 2.5% so far in 2020.

Earlier in October this year, CytoDyn continued to work on the study with the goal of hitting the primary endpoint after a review and recommendation from the DSMC (Data Safety Monitoring Committee). The DSMC provided its recommendation after going through the data related to 195 patients.

Disclosure: We hold no position in CYDY stock.

Latest article

Alibaba Group Holding Limited (OTCMKTS:BABAF) Big Volume with Possible 60% Upside

Alibaba Group Holding Limited (OTCMKTS:  BABAF) is an over the counter stock traded on the OTC Pink markets in the Consumer Discretionary...

Trans Global Group Inc (OTCMKTS:TGGI) Stock In Focus After Operational Updates

The Trans Global Group Inc (OTCMKTS:TGGI) stock may not have been in the news today yet but it...

Why Hycroft Mining (NASDAQ:HYMC) Stock Shot Up 700%

If you are on the hunt for stocks that may have made major gains over the course of the past week, then...

Secure Paymentz releases banking software demo on Github

This is a paid announcement from one of our advertising partners. How to Leverage Your Trading Position by Secure...

Advanced Asset Management Announces New Website Launch

This is a paid announcement from one of our advertising partners. Financial Planner in Grandville, Michigan
Şehirler arası nakliyat ve Şehirler arası taşımacılık konusunda en uygun fiyatlar ve en kaliteli hizmet.
ofis taşıma firmaları ve ofis taşıma konusunda en uygun fiyatlar ve en kaliteli hizmet.
SmsVerifyer.com Affordable best sms verification service